fenoldopam has been researched along with Coronary Disease in 5 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients." | 5.06 | A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. ( Jeffrey, RF; Lee, MR; MacDonald, TM; Muir, AL, 1990) |
| "Fenoldopam is a selective dopamine-receptor agonist with renoprotective properties." | 1.31 | Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. ( Madyoon, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kini, AA | 1 |
| Sharma, SK | 1 |
| Madyoon, H | 1 |
| Joseph, EC | 1 |
| Shi, Y | 1 |
| Zalewski, A | 1 |
| Bravette, B | 1 |
| Maroko, AR | 1 |
| Maroko, PR | 1 |
| MacDonald, TM | 1 |
| Jeffrey, RF | 1 |
| Muir, AL | 1 |
| Lee, MR | 1 |
1 review available for fenoldopam and Coronary Disease
| Article | Year |
|---|---|
Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and DA(1) agonists.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Coronary Disease; Cyclic Nucleotide Phosphodiesterases | 2000 |
2 trials available for fenoldopam and Coronary Disease
| Article | Year |
|---|---|
Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Chi-Square Distributio | 2001 |
A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Body Weight; Coronary Disease; Dop | 1990 |
2 other studies available for fenoldopam and Coronary Disease
| Article | Year |
|---|---|
Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
Topics: Acute Kidney Injury; Aged; Case-Control Studies; Contrast Media; Coronary Angiography; Coronary Dise | 2001 |
Selective dopamine-1 receptor agonist augments regional myocardial blood flow: comparison of fenoldopam and dopamine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Constriction; Coronary Circulat | 1992 |